vTv Therapeutics (VTVT) Shares Outstanding (Weighted Average) (2014 - 2026)

vTv Therapeutics has disclosed Shares Outstanding (Weighted Average) across 13 years of filings, most recently posting $12.4 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $12.4 million, up 88.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.4 million (up 88.51% YoY), and the FY2025 annual result was $8.4 million, up 45.96% from the prior year.
• Shares Outstanding (Weighted Average) came in at $12.4 million for Q1 2026 at vTv Therapeutics, up from $8.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $80.5 million in Q3 2022 to a low of $1.9 million in Q4 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $5.8 million (2024), against an average of $16.9 million.
• Across the five-year window, Shares Outstanding (Weighted Average) sank 97.41% in 2023 and surged 176.79% in 2024, its largest moves.
• vTv Therapeutics' Shares Outstanding (Weighted Average) stood at $1.9 million in 2022, then rose by 8.6% to $2.1 million in 2023, then jumped by 176.79% to $5.8 million in 2024, then surged by 45.96% to $8.4 million in 2025, then surged by 47.32% to $12.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $12.4 million (Q1 2026), $8.4 million (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.